These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 10790000)

  • 1. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial.
    Cox DJ; Merkel RL; Kovatchev B; Seward R
    J Nerv Ment Dis; 2000 Apr; 188(4):230-4. PubMed ID: 10790000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD.
    Verster JC; Roth T
    J Clin Psychopharmacol; 2014 Oct; 34(5):633-6. PubMed ID: 24978156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
    Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder.
    Cox DJ; Humphrey JW; Merkel RL; Penberthy JK; Kovatchev B
    J Am Board Fam Pract; 2004; 17(4):235-9. PubMed ID: 15243010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm.
    Biederman J; Fried R; Hammerness P; Surman C; Mehler B; Petty CR; Faraone SV; Miller C; Bourgeois M; Meller B; Godfrey KM; Reimer B
    J Psychiatr Res; 2012 Apr; 46(4):484-91. PubMed ID: 22277301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD).
    Sobanski E; Sabljic D; Alm B; Skopp G; Kettler N; Mattern R; Strohbeck-Kühner P
    J Neural Transm (Vienna); 2008; 115(2):347-56. PubMed ID: 18200437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADHD, methylphenidate and driving: does some legislation endanger public health?
    Verster JC; Cox DJ
    J Psychopharmacol; 2008 May; 22(3):227-9. PubMed ID: 18541623
    [No Abstract]   [Full Text] [Related]  

  • 9. Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Moore M; Burket R; Merkel RL; Mikami AY; Kovatchev B
    J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):1-10. PubMed ID: 18294083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder.
    Barkley RA; Murphy KR; O'Connell T; Connor DF
    J Safety Res; 2005; 36(2):121-31. PubMed ID: 15896352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial.
    Verster JC; Bekker EM; de Roos M; Minova A; Eijken EJ; Kooij JJ; Buitelaar JK; Kenemans JL; Verbaten MN; Olivier B; Volkerts ER
    J Psychopharmacol; 2008 May; 22(3):230-7. PubMed ID: 18308788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
    Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
    Biederman J; Quinn D; Weiss M; Markabi S; Weidenman M; Edson K; Karlsson G; Pohlmann H; Wigal S
    Paediatr Drugs; 2003; 5(12):833-41. PubMed ID: 14658924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance.
    Barkley RA; Cox D
    J Safety Res; 2007; 38(1):113-28. PubMed ID: 17303170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate enhances cognitive performance in adults with poor baseline capacities regardless of attention-deficit/hyperactivity disorder diagnosis.
    Agay N; Yechiam E; Carmel Z; Levkovitz Y
    J Clin Psychopharmacol; 2014 Apr; 34(2):261-5. PubMed ID: 24525641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.
    Kooij JJ; Burger H; Boonstra AM; Van der Linden PD; Kalma LE; Buitelaar JK
    Psychol Med; 2004 Aug; 34(6):973-82. PubMed ID: 15554568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review.
    Gobbo MA; Louzã MR
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1425-43. PubMed ID: 25044052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.